Clinical trialNCT03806426UnknownPhase 3Interventional

Effect of EPA-FFA on Polypectomy in Familial Adenomatous Polyposis

SponsorS.L.A. Pharma AGEnrollment204Familial Adenomatous Polyposis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of EPA-FFA gastro resistant capsules in FAP.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Luigi Ricciardiello, MD
Associate Professor of Gastroenterology, University of Bologna
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Italy

University of Bologna and St.Orsola-Malpighi Hospital
Bologna, Italy

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Eicosapentaenoic acid free fatty acidPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 5 Dec 2018
Primary completion: 30 Jun 2024
Completion: 31 Jul 2024
Last update posted: 25 Apr 2024
Registered enrollment: 204
Registry id: NCT03806426

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.